brentuximab,doxorubicin hydrochloride,dacarbazine,filgrastim,pegfilgrastim,nivolumab,vinblastine sulfate
seagen,amgen,bms
['hodgkin', 'lymphoma', 'congrat', 'nivo', 's1826']
huge congratulations to dr herrera and all colleagues on the #asco23 plenary presentation on s1826. 1l hodgkin lymphoma with advanced stage: pfs hr 0.48 favoring nivo-avd over bv-avd, 94% at 1 year. dr lacasce described as practice changing , eagerly awaiting &gt; follow up 
Director of Clinical Research, Section Chief Aggressive Lymphoma @MDAndersonNews, @ASCO Assoc Board Treasurer & Govt Relations Committee Chair, Opinions mine